• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个最小连续时间 Markov 药效计量学模型。

A Minimal Continuous-Time Markov Pharmacometric Model.

机构信息

Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-75124, Uppsala, Sweden.

出版信息

AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.

DOI:10.1208/s12248-017-0109-1
PMID:28634883
Abstract

In this work, an alternative model to discrete-time Markov model (DTMM) or standard continuous-time Markov model (CTMM) for analyzing ordered categorical data with Markov properties is presented: the minimal CTMM (mCTMM). Through a CTMM reparameterization and under the assumption that the transition rate between two consecutive states is independent on the state, the Markov property is expressed through a single parameter, the mean equilibration time, and the steady-state probabilities are described by a proportional odds (PO) model. The mCTMM performance was evaluated and compared to the PO model (ignoring Markov features) and to published Markov models using three real data examples: the four-state fatigue and hand-foot syndrome data in cancer patients initially described by DTMM and the 11-state Likert pain score data in diabetic patients previously analyzed with a count model including Markovian transition probability inflation. The mCTMM better described the data than the PO model, and adequately predicted the average number of transitions per patient and the maximum achieved scores in all examples. As expected, mCTMM could not describe the data as well as more flexible DTMM but required fewer estimated parameters. The mCTMM better fitted Likert data than the count model. The mCTMM enables to explore the effect of potential predictive factors such as drug exposure and covariates, on ordered categorical data, while accounting for Markov features, in cases where DTMM and/or standard CTMM is not applicable or conveniently implemented, e.g., non-uniform time intervals between observations or large number of categories.

摘要

在这项工作中,提出了一种替代离散时间马尔可夫模型 (DTMM) 或标准连续时间马尔可夫模型 (CTMM) 的方法,用于分析具有马尔可夫性质的有序分类数据:最小 CTMM (mCTMM)。通过 CTMM 的重新参数化,并假设两个连续状态之间的转移率与状态无关,马尔可夫性质通过单个参数表示,即平均平衡时间,稳态概率由比例优势 (PO) 模型描述。通过三个真实数据示例评估了 mCTMM 的性能,并与 PO 模型(忽略马尔可夫特征)和已发表的马尔可夫模型进行了比较:最初用 DTMM 描述的癌症患者的四状态疲劳和手足综合征数据和以前用包含马尔可夫转移概率膨胀的计数模型分析的糖尿病患者的 11 状态李克特疼痛评分数据。mCTMM 比 PO 模型更好地描述了数据,并且在所有示例中都充分预测了每个患者的平均转移次数和最大达到的分数。正如预期的那样,mCTMM 不能像更灵活的 DTMM 那样很好地描述数据,但需要更少的估计参数。mCTMM 比计数模型更适合描述李克特数据。mCTMM 能够在考虑到马尔可夫特征的情况下,探索药物暴露和协变量等潜在预测因素对有序分类数据的影响,而在 DTMM 和/或标准 CTMM 不适用或不方便实施的情况下,例如观察之间的非均匀时间间隔或大量类别。

相似文献

1
A Minimal Continuous-Time Markov Pharmacometric Model.一个最小连续时间 Markov 药效计量学模型。
AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.
2
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.维莫德吉肌肉痉挛不良事件的纵向有序分类数据分析:不同药代动力学模型的比较
CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):96-105. doi: 10.1002/psp4.12487. Epub 2020 Jan 30.
3
Likert pain score modeling: a Markov integer model and an autoregressive continuous model.李克特疼痛评分建模:马尔可夫整数模型和自回归连续模型。
Clin Pharmacol Ther. 2012 May;91(5):820-8. doi: 10.1038/clpt.2011.301. Epub 2012 Mar 21.
4
Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM.在 NONMEM 中使用双变量混合隐马尔可夫模型处理潜在离散变量。
J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):591-604. doi: 10.1007/s10928-019-09658-z. Epub 2019 Oct 26.
5
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.使用马尔可夫混合效应模型对自发报告的副作用进行建模。
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):261-81. doi: 10.1007/s10928-005-0021-7. Epub 2005 Nov 7.
6
Evaluation of type I error rates when modeling ordered categorical data in NONMEM.在NONMEM中对有序分类数据进行建模时I类错误率的评估。
J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):61-74. doi: 10.1023/b:jopa.0000029489.97168.a9.
7
Population pharmacokinetic model of lithium and drug compliance assessment.锂的群体药代动力学模型与药物依从性评估
Eur Neuropsychopharmacol. 2016 Dec;26(12):1868-1876. doi: 10.1016/j.euroneuro.2016.11.005. Epub 2016 Nov 16.
8
Semi-Markov Arnason-Schwarz models.半马尔可夫阿纳森 - 施瓦茨模型
Biometrics. 2016 Jun;72(2):619-28. doi: 10.1111/biom.12446. Epub 2015 Nov 19.
9
A scalable approach for continuous time Markov models with covariates.具有协变量的连续时间马尔可夫模型的可扩展方法。
Biostatistics. 2024 Jul 1;25(3):681-701. doi: 10.1093/biostatistics/kxad012.
10
A hybrid landmark Aalen-Johansen estimator for transition probabilities in partially non-Markov multi-state models.一种用于部分非马尔可夫多状态模型中转移概率的混合地标 Aalen-Johansen 估计量。
Lifetime Data Anal. 2021 Oct;27(4):737-760. doi: 10.1007/s10985-021-09534-4. Epub 2021 Sep 30.

引用本文的文献

1
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.一种用于多发性骨髓瘤患者接受埃拉纳单抗给药后细胞因子释放综合征发病率和病程的新型两部分混合模型。
Clin Pharmacol Ther. 2025 Jun;117(6):1687-1695. doi: 10.1002/cpt.3533. Epub 2025 Feb 16.
2
A tutorial on pharmacometric Markov models.药物计量马尔可夫模型教程。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):197-216. doi: 10.1002/psp4.13278. Epub 2024 Dec 13.
3
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.

本文引用的文献

1
Transition modeling of neuropsychiatric impairment in HIV.HIV相关神经精神障碍的转换模型
Comput Biol Med. 2016 Jun 1;73:141-6. doi: 10.1016/j.compbiomed.2016.04.011. Epub 2016 Apr 15.
2
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.在接受培塞丽珠治疗的类风湿关节炎患者中,ACR20、ACR50 和 ACR70 改善评分的同时暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3(10):e143. doi: 10.1038/psp.2014.41.
3
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.
一种非酒精性脂肪性肝病纤维化发展的马尔可夫模型可预测临床队列中的纤维化进展。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2038-2049. doi: 10.1002/psp4.13052. Epub 2023 Oct 3.
4
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.肿瘤临床药物开发中建模和模拟实践的全面监管和行业审查。
J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):147-172. doi: 10.1007/s10928-023-09850-2. Epub 2023 Mar 4.
5
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.PK/PD 模型将 COVID-19 相关临床症状的快速缓解与巴瑞替尼单药或巴瑞替尼联合埃特司韦单抗治疗后 SARS-CoV-2 病毒载量的降低联系起来。
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):721-730. doi: 10.1002/psp4.12784. Epub 2022 Apr 5.
6
Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.基于项目的药代动力学模型提高决策信心:一项 II 期安慰剂对照试验的说明。
AAPS J. 2021 Jun 2;23(4):79. doi: 10.1208/s12248-021-00600-1.
7
A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation.在程序镇静中,当雷米唑仑与芬太尼联合使用时,一种用于确定雷米唑仑诱导镇静的群体药代动力学 Markov 混合效应模型。
Clin Transl Sci. 2021 Jul;14(4):1554-1565. doi: 10.1111/cts.13023. Epub 2021 Apr 9.
8
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.采用 Markov 建模方法评估卡培他滨所致手足综合征患者报告的严重程度。
Cancer Chemother Pharmacol. 2020 Sep;86(3):435-444. doi: 10.1007/s00280-020-04128-7. Epub 2020 Aug 27.
9
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.维莫德吉肌肉痉挛不良事件的纵向有序分类数据分析:不同药代动力学模型的比较
CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):96-105. doi: 10.1002/psp4.12487. Epub 2020 Jan 30.
10
A Bounded Integer Model for Rating and Composite Scale Data.用于评分和复合量表数据的有界整数模型。
AAPS J. 2019 Jun 6;21(4):74. doi: 10.1208/s12248-019-0343-9.
舒尼替尼治疗的 GIST 患者不良事件和总生存的预测因子的 PKPD 模型。
CPT Pharmacometrics Syst Pharmacol. 2013 Dec 4;2(12):e85. doi: 10.1038/psp.2013.62.
4
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.VEGF、sVEGFR-2、sVEGFR-3 和 sKIT 的 PKPD 模型作为舒尼替尼治疗 GIST 后肿瘤动力学和总生存的预测因子
CPT Pharmacometrics Syst Pharmacol. 2013 Nov 20;2(11):e84. doi: 10.1038/psp.2013.61.
5
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.NONMEM 模型与仿真工作平台:Pirana、PsN 和 Xpose 使用教程。
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2(6):e50. doi: 10.1038/psp.2013.24.
6
Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.采用 Markov 元素对锥体外系副作用严重程度进行药代动力学-药效学建模。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e1. doi: 10.1038/psp.2012.9.
7
Likert pain score modeling: a Markov integer model and an autoregressive continuous model.李克特疼痛评分建模:马尔可夫整数模型和自回归连续模型。
Clin Pharmacol Ther. 2012 May;91(5):820-8. doi: 10.1038/clpt.2011.301. Epub 2012 Mar 21.
8
A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.基于机制的吸收建模方法:胃肠传输时间(GITT)模型。
AAPS J. 2012 Jun;14(2):155-63. doi: 10.1208/s12248-012-9324-y.
9
A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.一种半机械论建模策略,用于描述新的改良释放制剂给药后区域性吸收特性和预测血浆浓度的前瞻性。
Pharm Res. 2012 Feb;29(2):574-84. doi: 10.1007/s11095-011-0595-2. Epub 2011 Sep 23.
10
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.接受抗血管生成药物 E7080 治疗的癌症患者的高血压和蛋白尿模型。
J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):347-63. doi: 10.1007/s10928-010-9164-2. Epub 2010 Jul 23.